GlobeNewswire: BioSyent Inc. Contains the last 10 of 203 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T10:50:13ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853667/0/en/BioSyent-Announces-Grant-of-Restricted-Share-Units.html?f=22&fvtc=4&fvtv=36948BioSyent Announces Grant of Restricted Share Units2024-03-27T22:34:48Z<![CDATA[MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third anniversary of the applicable grant date.]]>https://www.globenewswire.com/news-release/2024/03/13/2845890/0/en/BioSyent-Releases-Financial-Results-for-Fourth-Quarter-and-Full-Year-2023.html?f=22&fvtc=4&fvtv=36948BioSyent Releases Financial Results for Fourth Quarter and Full Year 20232024-03-13T21:30:00Z<![CDATA[MISSISSAUGA, Ontario, March 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2023. Key highlights include:]]>https://www.globenewswire.com/news-release/2024/03/06/2841806/0/en/BioSyent-Schedules-Fourth-Quarter-and-Full-Year-2023-Earnings-Release-for-March-13-2024.html?f=22&fvtc=4&fvtv=36948BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 20242024-03-06T21:30:00Z<![CDATA[MISSISSAUGA, Ontario, March 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2023 on Wednesday, March 13th after market hours. A presentation on the Company’s fourth quarter and full year 2023 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.]]>https://www.globenewswire.com/news-release/2024/02/21/2832699/0/en/BioSyent-Named-to-2024-TSX-Venture-50.html?f=22&fvtc=4&fvtv=36948BioSyent Named to 2024 TSX Venture 502024-02-21T13:00:00Z<![CDATA[MISSISSAUGA, Ontario, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named to the 2024 TSX Venture 50 list as one of the top performers on the TSX Venture Exchange.]]>https://www.globenewswire.com/news-release/2024/02/06/2824762/0/en/BioSyent-Declares-First-Quarter-2024-Dividend.html?f=22&fvtc=4&fvtv=36948BioSyent Declares First Quarter 2024 Dividend2024-02-06T21:30:00Z<![CDATA[MISSISSAUGA, Ontario, Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. This first quarter 2024 dividend of $0.045 per common share represents a 12.5% increase from the fourth quarter 2023 dividend of $0.040 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.]]>https://www.globenewswire.com/news-release/2023/12/13/2795498/0/en/BioSyent-Announces-Renewal-of-Normal-Course-Issuer-Bid.html?f=22&fvtc=4&fvtv=36948BioSyent Announces Renewal of Normal Course Issuer Bid2023-12-13T13:00:00Z<![CDATA[MISSISSAUGA, Ontario , Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 650,000 of its common shares (“Shares”) over a 12-month period, representing approximately 5.53% of the Shares outstanding as of December 13, 2023.]]>https://www.globenewswire.com/news-release/2023/11/20/2783237/0/en/BioSyent-Announces-the-Availability-of-Gelclair-in-Canada.html?f=22&fvtc=4&fvtv=36948BioSyent Announces the Availability of Gelclair® in Canada2023-11-20T13:30:00Z<![CDATA[New Treatment for Painful Mouth Sores Due to Cancer Therapy New Treatment for Painful Mouth Sores Due to Cancer Therapy]]>https://www.globenewswire.com/news-release/2023/11/16/2781761/0/en/BioSyent-Releases-Q3-and-YTD-2023-Financial-Results.html?f=22&fvtc=4&fvtv=36948BioSyent Releases Q3 and YTD 2023 Financial Results2023-11-16T13:00:00Z<![CDATA[MISSISSAUGA, Ontario, Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2023. Key highlights include:]]>https://www.globenewswire.com/news-release/2023/11/15/2781442/0/en/BioSyent-Declares-Fourth-Quarter-2023-Dividend.html?f=22&fvtc=4&fvtv=36948BioSyent Declares Fourth Quarter 2023 Dividend2023-11-15T21:34:42Z<![CDATA[MISSISSAUGA, Ontario, Nov. 15, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2023, to shareholders of record at the close of business on November 30, 2023. This fourth quarter 2023 dividend compares with the third quarter 2023 dividend of $0.04 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.]]>https://www.globenewswire.com/news-release/2023/11/09/2777307/0/en/BioSyent-Schedules-Q3-and-YTD-2023-Earnings-Release-for-November-16-2023.html?f=22&fvtc=4&fvtv=36948BioSyent Schedules Q3 and YTD 2023 Earnings Release for November 16, 20232023-11-09T13:00:00Z<![CDATA[MISSISSAUGA, Ontario, Nov. 09, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2023 on Thursday, November 16, 2023 before market hours. A presentation on the Company’s third quarter and year-to-date 2023 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.]]>